The Institute of Cancer Sciences haemato-oncology researchers are improving outcomes for patients with lymphoma, leukaemia and myeloma through internationally competitive research.
Strong links have been forged with Leukaemia and Lymphoma Research, Myeloma UK, Cancer Research UK and many pharmaceutical companies. Collaborations exist with other academic researchers throughout the world. In all of this, our one aim is to develop new and better treatments for patients with haematological cancer by:
- Improving therapies through personalised medicine, investigating the factors which determine the best course of treatment for the patient as an individual
- Investigating drug resistance, elucidating how leukaemia and lymphoma cancer cells are able to adapt and recover after successful drug treatments
- Identifying novel targets for treatment through blood-borne and imaging biomarker discovery programmes
The Centre for Haematological Oncology comprises clinical and non-clinical academic members as well as researchers. It works closely with NHS clinicians and colleagues in the Cancer Research UK Manchester Institute (CRUK MI). Our primary aim is to develop new and better treatments for patients with haematological cancer.